In-depth: After a rough 17 years, is Biovac finally on track?

In-depth: After a rough 17 years, is Biovac finally on track?

South Africa has struggled to secure adequate stock of urgently needed COVID-19 vaccines. This has raised questions about the state of the country’s local vaccine manufacturing capacity and why, after almost two decades of government support, South Africa’s partially state-owned vaccine manufacturer Biovac is not better positioned to respond to the pandemic. Catherine Tomlinson investigates.

Read More

IN-DEPTH: The slow motion race for a TB vaccine

IN-DEPTH: The slow motion race for a TB vaccine

In recent months, the world has seen unprecedented investment in new vaccines. Yet, while a COVID-19 vaccine proven to be safe and effective may be less than a year away, a new tuberculosis vaccine might only be ready to be rolled out in a decade, despite a massive head start over COVID-19. Amy Green takes a closer look at the race for a new vaccine for the world’s top infectious disease killer.

Read More